Do analysts recommend SNOA or KZIA?

Novogen has a consensus target price of $21.00, indicating a potential upside of 80.72%. Given Novogen's stronger consensus rating and higher possible upside, analysts plainly believe Novogen is more favorable than Sonoma Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Novogen 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has stronger earnings and valuation, SNOA or KZIA?

Sonoma Pharmaceuticals has higher revenue and earnings than Novogen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sonoma Pharmaceuticals $14.29M 0.40 -$3.46M -$2.04 N/A Novogen $30K 639.10 -$13.41M N/A N/A

Do analysts recommend SNOA or QNCX?

Quince Therapeutics has a consensus price target of $65.00, indicating a potential upside of 6,241.46%. Given Quince Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Quince Therapeutics is more favorable than Sonoma Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Quince Therapeutics 2 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.71

Do analysts recommend CTXR or SNOA?

Citius Pharmaceuticals currently has a consensus target price of $5.00, indicating a potential upside of 749.47%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Citius Pharmaceuticals is more favorable than Sonoma Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Citius Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate AEON or SNOA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AEON Biopharma 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00 Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer ZIVO or SNOA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Sonoma Pharmaceuticals (SNOA) Competitors

$1.18 +0.03 (+2.16%)

As of 10:10 AM Eastern

Compare

SNOA vs. KZIA, QNCX, CTXR, AEON, and ZIVO

Should you buy Sonoma Pharmaceuticals stock or one of its competitors? MarketBeat compares Sonoma Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sonoma Pharmaceuticals include Novogen (KZIA), Quince Therapeutics (QNCX), Citius Pharmaceuticals (CTXR), AEON Biopharma (AEON), and ZIVO Bioscience (ZIVO). These companies are all part of the "pharmaceutical products" industry.

How does Sonoma Pharmaceuticals compare to Novogen?

Sonoma Pharmaceuticals (NASDAQ:SNOA) and Novogen (NASDAQ:KZIA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

In the previous week, Sonoma Pharmaceuticals and Sonoma Pharmaceuticals both had 2 articles in the media. Sonoma Pharmaceuticals' average media sentiment score of 1.44 beat Novogen's score of 0.63 indicating that Sonoma Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Sonoma Pharmaceuticals	Positive
Novogen	Positive

Novogen has a consensus target price of $21.00, indicating a potential upside of 80.72%. Given Novogen's stronger consensus rating and higher possible upside, analysts plainly believe Novogen is more favorable than Sonoma Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Novogen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Sonoma Pharmaceuticals has higher revenue and earnings than Novogen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sonoma Pharmaceuticals	$14.29M	0.40	-$3.46M	-$2.04	N/A
Novogen	$30K	639.10	-$13.41M	N/A	N/A

Novogen has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -19.04%. Novogen's return on equity of 0.00% beat Sonoma Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sonoma Pharmaceuticals	-19.04%	-42.56%	-11.97%
Novogen	N/A	N/A	N/A

Sonoma Pharmaceuticals has a beta of 1.29, indicating that its share price is 29% more volatile than the broader market. Comparatively, Novogen has a beta of 2.17, indicating that its share price is 117% more volatile than the broader market.

2.0% of Sonoma Pharmaceuticals shares are owned by institutional investors. Comparatively, 30.9% of Novogen shares are owned by institutional investors. 2.3% of Sonoma Pharmaceuticals shares are owned by insiders. Comparatively, 1.0% of Novogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Novogen beats Sonoma Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Sonoma Pharmaceuticals compare to Quince Therapeutics?

Sonoma Pharmaceuticals (NASDAQ:SNOA) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, profitability and media sentiment.

Sonoma Pharmaceuticals has a beta of 1.29, suggesting that its stock price is 29% more volatile than the broader market. Comparatively, Quince Therapeutics has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market.

2.0% of Sonoma Pharmaceuticals shares are owned by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are owned by institutional investors. 2.3% of Sonoma Pharmaceuticals shares are owned by company insiders. Comparatively, 7.1% of Quince Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Quince Therapeutics has a consensus price target of $65.00, indicating a potential upside of 6,241.46%. Given Quince Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Quince Therapeutics is more favorable than Sonoma Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

Quince Therapeutics has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -19.04%. Sonoma Pharmaceuticals' return on equity of -42.56% beat Quince Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sonoma Pharmaceuticals	-19.04%	-42.56%	-11.97%
Quince Therapeutics	N/A	-372.88%	-67.99%

Sonoma Pharmaceuticals has higher revenue and earnings than Quince Therapeutics. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sonoma Pharmaceuticals	$14.29M	0.40	-$3.46M	-$2.04	N/A
Quince Therapeutics	N/A	N/A	-$83.98M	-$10.62	N/A

In the previous week, Sonoma Pharmaceuticals and Sonoma Pharmaceuticals both had 2 articles in the media. Quince Therapeutics' average media sentiment score of 1.80 beat Sonoma Pharmaceuticals' score of 1.44 indicating that Quince Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Sonoma Pharmaceuticals	Positive
Quince Therapeutics	Very Positive

Summary

Quince Therapeutics beats Sonoma Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Sonoma Pharmaceuticals compare to Citius Pharmaceuticals?

Citius Pharmaceuticals (NASDAQ:CTXR) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and media sentiment.

Citius Pharmaceuticals has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market. Comparatively, Sonoma Pharmaceuticals has a beta of 1.29, meaning that its share price is 29% more volatile than the broader market.

Citius Pharmaceuticals has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -19.04%. Sonoma Pharmaceuticals' return on equity of -42.56% beat Citius Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Pharmaceuticals	N/A	-61.09%	-35.36%
Sonoma Pharmaceuticals	-19.04%	-42.56%	-11.97%

Sonoma Pharmaceuticals has higher revenue and earnings than Citius Pharmaceuticals. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$2.13	N/A
Sonoma Pharmaceuticals	$14.29M	0.40	-$3.46M	-$2.04	N/A

In the previous week, Citius Pharmaceuticals and Citius Pharmaceuticals both had 2 articles in the media. Sonoma Pharmaceuticals' average media sentiment score of 1.44 beat Citius Pharmaceuticals' score of 0.63 indicating that Sonoma Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Citius Pharmaceuticals	Positive
Sonoma Pharmaceuticals	Positive

Citius Pharmaceuticals currently has a consensus target price of $5.00, indicating a potential upside of 749.47%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Citius Pharmaceuticals is more favorable than Sonoma Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

16.9% of Citius Pharmaceuticals shares are held by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. 5.0% of Citius Pharmaceuticals shares are held by company insiders. Comparatively, 2.3% of Sonoma Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Citius Pharmaceuticals and Sonoma Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Sonoma Pharmaceuticals compare to AEON Biopharma?

AEON Biopharma (NASDAQ:AEON) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Sonoma Pharmaceuticals has higher revenue and earnings than AEON Biopharma. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AEON Biopharma	N/A	N/A	-$36.63M	-$5.00	N/A
Sonoma Pharmaceuticals	$14.29M	0.40	-$3.46M	-$2.04	N/A

22.8% of AEON Biopharma shares are owned by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are owned by institutional investors. 9.4% of AEON Biopharma shares are owned by company insiders. Comparatively, 2.3% of Sonoma Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

AEON Biopharma has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market. Comparatively, Sonoma Pharmaceuticals has a beta of 1.29, indicating that its stock price is 29% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AEON Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

AEON Biopharma has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -19.04%. AEON Biopharma's return on equity of 0.00% beat Sonoma Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AEON Biopharma	N/A	N/A	-994.63%
Sonoma Pharmaceuticals	-19.04%	-42.56%	-11.97%

In the previous week, AEON Biopharma had 2 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 4 mentions for AEON Biopharma and 2 mentions for Sonoma Pharmaceuticals. Sonoma Pharmaceuticals' average media sentiment score of 1.44 beat AEON Biopharma's score of 1.07 indicating that Sonoma Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
AEON Biopharma	Positive
Sonoma Pharmaceuticals	Positive

Summary

AEON Biopharma beats Sonoma Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Sonoma Pharmaceuticals compare to ZIVO Bioscience?

ZIVO Bioscience (NASDAQ:ZIVO) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Sonoma Pharmaceuticals had 2 more articles in the media than ZIVO Bioscience. MarketBeat recorded 2 mentions for Sonoma Pharmaceuticals and 0 mentions for ZIVO Bioscience. Sonoma Pharmaceuticals' average media sentiment score of 1.44 beat ZIVO Bioscience's score of 0.00 indicating that Sonoma Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
ZIVO Bioscience	Neutral
Sonoma Pharmaceuticals	Positive

12.8% of ZIVO Bioscience shares are held by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. 21.5% of ZIVO Bioscience shares are held by company insiders. Comparatively, 2.3% of Sonoma Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Sonoma Pharmaceuticals has higher revenue and earnings than ZIVO Bioscience. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Sonoma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZIVO Bioscience	$15.85K	1,152.61	-$7.78M	-$1.71	N/A
Sonoma Pharmaceuticals	$14.29M	0.40	-$3.46M	-$2.04	N/A

ZIVO Bioscience has a beta of 0.04, suggesting that its stock price is 96% less volatile than the broader market. Comparatively, Sonoma Pharmaceuticals has a beta of 1.29, suggesting that its stock price is 29% more volatile than the broader market.

ZIVO Bioscience has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -19.04%. ZIVO Bioscience's return on equity of 0.00% beat Sonoma Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ZIVO Bioscience	N/A	N/A	-2,240.92%
Sonoma Pharmaceuticals	-19.04%	-42.56%	-11.97%

Summary

Sonoma Pharmaceuticals beats ZIVO Bioscience on 8 of the 14 factors compared between the two stocks.

Get Sonoma Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNOA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNOA vs. The Competition

Export

Metric	Sonoma Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.68M	$2.89B	$6.24B	$12.48B
Dividend Yield	N/A	1.79%	2.69%	5.30%
P/E Ratio	-0.58	17.62	21.09	24.35
Price / Sales	0.40	485.00	561.45	126.00
Price / Cash	N/A	56.38	42.31	57.88
Price / Book	0.43	3.84	9.95	6.72
Net Income	-$3.46M	$75.85M	$3.56B	$337.08M
7 Day Performance	9.72%	-2.00%	-0.07%	1.63%
1 Month Performance	-1.25%	23.28%	5.08%	6.29%
1 Year Performance	-66.62%	21.79%	28.39%	35.50%

Sonoma Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNOA Sonoma Pharmaceuticals	1.2495 of 5 stars	$1.19 +2.2%	N/A	-66.0%	$5.68M	$14.29M	N/A	180	Positive News
KZIA Novogen	2.4493 of 5 stars	$12.30 -1.7%	$21.00 +70.7%	+211.9%	$20.33M	$42K	N/A	12	News Coverage Gap Up
QNCX Quince Therapeutics	2.1441 of 5 stars	$1.22 +1.3%	$65.00 +5,249.8%	-90.1%	$19.64M	N/A	N/A	60	News Coverage Positive News
CTXR Citius Pharmaceuticals	3.0503 of 5 stars	$0.71 +1.7%	$5.00 +605.2%	-21.6%	$19.46M	$5.61M	N/A	20
AEON AEON Biopharma	1.7421 of 5 stars	$0.76 -1.8%	N/A	+36.8%	$19.13M	N/A	4.20	5	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNOA) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sonoma Pharmaceuticals (SNOA) Competitors

SNOA vs. KZIA, QNCX, CTXR, AEON, and ZIVO

How does Sonoma Pharmaceuticals compare to Novogen?

Summary

How does Sonoma Pharmaceuticals compare to Quince Therapeutics?

Summary

How does Sonoma Pharmaceuticals compare to Citius Pharmaceuticals?

Summary

How does Sonoma Pharmaceuticals compare to AEON Biopharma?

Summary

How does Sonoma Pharmaceuticals compare to ZIVO Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNOA vs. The Competition

Sonoma Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sonoma Pharmaceuticals (SNOA) Competitors

SNOA vs. KZIA, QNCX, CTXR, AEON, and ZIVO

How does Sonoma Pharmaceuticals compare to Novogen?

Does the media refer more to SNOA or KZIA?

Do analysts recommend SNOA or KZIA?

Which has stronger earnings and valuation, SNOA or KZIA?

Is SNOA or KZIA more profitable?

Which has more risk & volatility, SNOA or KZIA?

Do institutionals and insiders believe in SNOA or KZIA?

Summary

How does Sonoma Pharmaceuticals compare to Quince Therapeutics?

Which has more volatility & risk, SNOA or QNCX?

Do insiders and institutionals believe in SNOA or QNCX?

Do analysts recommend SNOA or QNCX?

Is SNOA or QNCX more profitable?

Which has better valuation and earnings, SNOA or QNCX?

Does the media refer more to SNOA or QNCX?

Summary

How does Sonoma Pharmaceuticals compare to Citius Pharmaceuticals?

Which has more volatility and risk, CTXR or SNOA?

Is CTXR or SNOA more profitable?

Which has stronger valuation & earnings, CTXR or SNOA?

Does the media favor CTXR or SNOA?

Do analysts recommend CTXR or SNOA?

Do institutionals & insiders believe in CTXR or SNOA?

Summary

How does Sonoma Pharmaceuticals compare to AEON Biopharma?

Which has better valuation and earnings, AEON or SNOA?

Do insiders and institutionals hold more shares of AEON or SNOA?

Which has more volatility and risk, AEON or SNOA?

Do analysts rate AEON or SNOA?

Is AEON or SNOA more profitable?

Does the media favor AEON or SNOA?

Summary

How does Sonoma Pharmaceuticals compare to ZIVO Bioscience?

Do analysts prefer ZIVO or SNOA?

Does the media prefer ZIVO or SNOA?

Do institutionals and insiders have more ownership in ZIVO or SNOA?

Which has higher valuation and earnings, ZIVO or SNOA?

Which has more risk & volatility, ZIVO or SNOA?

Is ZIVO or SNOA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNOA vs. The Competition

Sonoma Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools